SCHEMBL278658

SCHEMBL278658

N/N=N/N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2017821 1.00
SCHEMBL2017820 1.00
SCHEMBL30860723 0.91
SCHEMBL29243216 0.91
SCHEMBL14025136 0.74
SCHEMBL380603 0.68
SCHEMBL2609929 0.68
SCHEMBL1101296 0.67
SCHEMBL20413229 0.63
SCHEMBL18959162 0.63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239756-A1 NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME MITSUBISHI TANABE PHARMA CORPORATION (JP) 2024-07-18 US disclosed
US-11912646-B2 Transmembrane pores formed by aromatic oligoamide foldamers and uses of same THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2024-02-27 US disclosed
US-11834421-B2 Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2023-12-05 US disclosed
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-10-12 US disclosed
US-20230322758-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS, INC. 2023-10-12 US disclosed
US-20230317967-A1 ORGANO-ALUMINUM ANALYTES FOR NONAQUEOUS REDOX FLOW BATTERIES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-10-05 US disclosed
US-20230303618-A1 TRIPTOLIDE CONJUGATES AND USES THEREOF REYOUNG CORPORATION (US) 2023-09-28 US disclosed
US-11718614-B2 Compounds and methods for treatment of hedgehog pathway associated conditions SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) 2023-08-08 US disclosed
US-20230242471-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-08-03 US disclosed
US-20230157161-A1 ORGANIC MATERIAL COMPOSITION AND APPLICATIONS THEREOF NINGBO LUMILAN ADVANCED MATERIALS CO., LTD. (CN) 2023-05-18 US disclosed
US-20080175856-A1 Enterococcus Antigens INTERCELL AG (AT) 2008-07-24 US disclosed
US-20080153112-A1 Antigens Targeted by Prevalent Pathogennic T Cells in Type 1 Diabetes and Uses Thereof ALBERT EINSTEIN COLLEGE OF MEDICINE 2008-06-26 US disclosed
US-20080096844-A1 Novel inhibitors of chymase JANSSEN PHARMACEUTICA, N.V. (BE) 2008-04-24 US disclosed
US-20080051453-A1 Sorbic acid analog co-crystals AMGEN INC. 2008-02-28 US disclosed
US-7314888-B1 Compounds and medicinal use thereof TOYAMA CHEMICAL CO., LTD. (JP) 2008-01-01 US disclosed
US-7309564-B2 Photothermographic material and image forming method FUJIFILM CORPORATION (JP) 2007-12-18 US disclosed
US-20070258147-A1 Redox-active structures and devices utilizing the same YEDA RESEARCH & DEVELOPMENT CO., LTD. (IL) 2007-11-08 US disclosed
US-20070179100-A1 Protected monomers ALNYLAM PHARMACEUTICALS, INC. 2007-08-02 US disclosed
US-20070148518-A1 Polymer electrolyte and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED 2007-06-28 US disclosed
US-7176214-B2 Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-13 US disclosed